Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

ERVE-1 (endogenous retrovirus group E member 1)

Written2020-06Luigi Cristiano
R&D Dep. (Aesthetic and medical biotechnologies research unit), Prestige, Terranuova Bracciolini, Italy; -

Abstract Endogenous retrovirus group E member 1, alias ERVE-1, is an integrated retroviral element of the human genome. Still poorly characterized, it maps on Chromosome 17 and it is reported for multiple sclerosis and systemic lupus erythematosus.

Keywords Endogenous retrovirus; ERVs; ERVE-1

(Note : for Links provided by Atlas : click)


endogenous retroviral sequence E, 1
endogenous retrovirus group E, member 1
HGNC (Hugo) ERVE-1
HGNC Alias symbHERV-E1
HGNC Previous nameERVE1
HGNC Previous nameendogenous retroviral sequence E, 1
 endogenous retrovirus group E, member 1
LocusID (NCBI) 85314
Atlas_Id 40490
Location 17q11.2  [Link to chromosome band 17q11]
Local_order Starts at 28,232,590 and ends at 28,235,281 bp from qter, reverse strand (GRCh38/hg38)
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)


Note Endogenous retrovirus group E member 1 (ERVE-1) is an integrated retroviral element of the human genome. It is known that human endogenous retroviruses (ERVs) and ERV-like sequences are part of the repetitive portions of the human genome and are remnants of infections of former exogenous retroviruses. They comprise about 8% of the human genome (Landers et al, 2001) and include solitary long terminal repeats (LTRs), non-retroviral sequences flanked by LTRs, and LTRs-like sequences (Mayer et al, 2011). ERVs are divided into various groups. ERVE-1 is member 1 of the group E of endogenous retroviruses and it maps on Chromosome 17, specifically on 17q11.2 (Campos-Sánchez and Sandoval-Carvajal, 2018; Taruscio et al, 2002). In addition, it starts at 28,232,590 and ends at 28,235,281 bp from qter (reverse strand). It is present in the Ensembl database with a sequence named ENSG00000267259. ERVE-1 DNA sequence shows a strong promoter sequence site located at +0.8 kb from the gene transcription start site.
  Figure. 1. ERVE-1 gene. The figure shows the locus on chromosome 17 of the ERVE-1 gene, its DNA and mRNA (reworked from;;
Transcription Usually, human ERVs are silenced epigenetically and are not transcribed (Kewitz and Staege, 2013), however, they are found to be transcribed in particular situations, such as under pathological conditions, and usually their transcription is initiated by promoter sequences within the proviral LTRs (Mayer et al, 2011).
ERVE-1 mRNA is 2,691 bp long with a reference sequence reported in GeneBank as BC037342. It is also present in the Ensembl database with a sequence named ERVE-1-201 (ENST00000592016.1) and it is considered to be a long non-coding RNA (lncRNA). Abundant ERVE-1 transcript was found in normal pancreas and thyroid tissues (Shiroma et al, 2001) and this suggests that it may play a role in their physiologic functions. In addition, the long terminal repeat (LTR)-derived promoter of ERVE-1 was found hypomethylated in placental cells whereas it was detected hypermethylated in blood cells (Ruebner et al, 2013; Reiss et al, 2007). This suggests that ERVE-1 could be transcribed in this tissue compared to others in which it is epigenetically silenced.
Pseudogene No observed pseudogenes for the ERVE-1 sequence.


Note It is well-known that human ERVs and ERV-like sequences no longer encode proteins because of the accumulation of nonsense mutations as a consequence of their ancient incorporation into the genome of the host (Mayer et al, 2011). For ERVE-1 sequence there is no protein reported.

Implicated in

Note Expression of ERVs is usually switched off (Kewitz and Staege, 2013) but the expression of ERVs and ERV-like sequences have been reported for a large number of human diseases, including cancer, however, their exact involvement and mechanism of action remain to be clarified (Mayer et al, 2011). ERVE-1 is poorly studied, however, it was reported for multiple sclerosis (MS) and Systemic lupus erythematosus (SLE).
Entity Multiple sclerosis (MS)
Note ERVE-1 could have biological functions in the pathogenesis of multiple sclerosis (MS) (Kim et al, 2008; Antony et al, 2007), however, as the disease is very complex, further studies are needed to understand its contribution.
Entity Systemic lupus erythematosus (SLE)
Note The expression level of ERVE-1 mRNA is found higher in lupus CD4+ T cells respect to healthy controls while the methylation of the LTR-derived promoter of ERVE-1 is found low in these patients (Suntsova et al, 2015; Wu et al, 2015). These data suggest that ERVE-1 is positively correlated with systemic lupus erythematosus (SLE) disease and that it is involved in its development (Wu et al, 2015).


Comparative expression of human endogenous retrovirus-W genes in multiple sclerosis
Antony JM, Zhu Y, Izad M, Warren KG, Vodjgani M, Mallet F, Power C
AIDS Res Hum Retroviruses 2007 Oct;23(10):1251-6.
Expression and Regulation of the Endogenous Retrovirus 3 in Hodgkin's Lymphoma Cells
Kewitz S, Staege MS
Front Oncol 2013 Jul 10;3:179.
PMID 23847767
Quantitative expression of the HERV-W env gene in human tissues
Kim HS, Ahn K, Kim DS
Arch Virol 2008;153(8):1587-91.
PMID 18604468
Initial sequencing and analysis of the human genome
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-Thomann Y, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R, French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A, Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S, Mullikin JC, Mungall A, Plumb R, Ross M, Shownkeen R, Sims S, Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA, Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissoe SL, Wendl MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB, Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T, Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett N, Cheng JF, Olsen A, Lucas S, Elkin C, Uberbacher E, Frazier M, Gibbs RA, Muzny DM, Scherer SE, Bouck JB, Sodergren EJ, Worley KC, Rives CM, Gorrell JH, Metzker ML, Naylor SL, Kucherlapati RS, Nelson DL, Weinstock GM, Sakaki Y, Fujiyama A, Hattori M, Yada T, Toyoda A, Itoh T, Kawagoe C, Watanabe H, Totoki Y, Taylor T, Weissenbach J, Heilig R, Saurin W, Artiguenave F, Brottier P, Bruls T, Pelletier E, Robert C, Wincker P, Smith DR, Doucette-Stamm L, Rubenfield M, Weinstock K, Lee HM, Dubois J, Rosenthal A, Platzer M, Nyakatura G, Taudien S, Rump A, Yang H, Yu J, Wang J, Huang G, Gu J, Hood L, Rowen L, Madan A, Qin S, Davis RW, Federspiel NA, Abola AP, Proctor MJ, Myers RM, Schmutz J, Dickson M, Grimwood J, Cox DR, Olson MV, Kaul R, Raymond C, Shimizu N, Kawasaki K, Minoshima S, Evans GA, Athanasiou M, Schultz R, Roe BA, Chen F, Pan H, Ramser J, Lehrach H, Reinhardt R, McCombie WR, de la Bastide M, Dedhia N, Blöcker H, Hornischer K, Nordsiek G, Agarwala R, Aravind L, Bailey JA, Bateman A, Batzoglou S, Birney E, Bork P, Brown DG, Burge CB, Cerutti L, Chen HC, Church D, Clamp M, Copley RR, Doerks T, Eddy SR, Eichler EE, Furey TS, Galagan J, Gilbert JG, Harmon C, Hayashizaki Y, Haussler D, Hermjakob H, Hokamp K, Jang W, Johnson LS, Jones TA, Kasif S, Kaspryzk A, Kennedy S, Kent WJ, Kitts P, Koonin EV, Korf I, Kulp D, Lancet D, Lowe TM, McLysaght A, Mikkelsen T, Moran JV, Mulder N, Pollara VJ, Ponting CP, Schuler G, Schultz J, Slater G, Smit AF, Stupka E, Szustakowki J, Thierry-Mieg D, Thierry-Mieg J, Wagner L, Wallis J, Wheeler R, Williams A, Wolf YI, Wolfe KH, Yang SP, Yeh RF, Collins F, Guyer MS, Peterson J, Felsenfeld A, Wetterstrand KA, Patrinos A, Morgan MJ, de Jong P, Catanese JJ, Osoegawa K, Shizuya H, Choi S, Chen YJ, Szustakowki J,
Nature 2001 Feb 15;409(6822):860-921.
PMID 11237011
A revised nomenclature for transcribed human endogenous retroviral loci
Mayer J, Blomberg J, Seal RL
Mob DNA 2011 May 4;2(1):7.
PMID 21542922
Widely variable endogenous retroviral methylation levels in human placenta
Reiss D, Zhang Y, Mager DL
Nucleic Acids Res 2007;35(14):4743-54.
PMID 17617638
Reduced syncytin-1 expression levels in placental syndromes correlates with epigenetic hypermethylation of the ERVW-1 promoter region
Ruebner M, Strissel PL, Ekici AB, Stiegler E, Dammer U, Goecke TW, Faschingbauer F, Fahlbusch FB, Beckmann MW, Strick R
PLoS One 2013;8(2):e56145.
PMID 23457515
Search for active endogenous retroviruses: identification and characterization of a HERV-E gene that is expressed in the pancreas and thyroid
Shiroma T, Sugimoto J, Oda T, Jinno Y, Kanaya F
J Hum Genet 2001;46(11):619-25.
PMID 11721880
Molecular functions of human endogenous retroviruses in health and disease
Suntsova M, Garazha A, Ivanova A, Kaminsky D, Zhavoronkov A, Buzdin A
Cell Mol Life Sci 2015 Oct;72(19):3653-75.
PMID 26082181
Organization and integration sites in the human genome of endogenous retroviral sequences belonging to HERV-E family
Taruscio D, Floridia G, Zoraqi GK, Mantovani A, Falbo V
Mamm Genome 2002 Apr;13(4):216-22.
PMID 11956766
DNA methylation modulates HERV-E expression in CD4+ T cells from systemic lupus erythematosus patients
Wu Z, Mei X, Zhao D, Sun Y, Song J, Pan W, Shi W
J Dermatol Sci 2015 Feb;77(2):110-6.
PMID 25595738


This paper should be referenced as such :
Cristiano L
ERVE-1 (endogenous retrovirus group E member 1)
Atlas Genet Cytogenet Oncol Haematol. 2021;25(2):63-65
Free journal version : [ pdf ]   [ DOI ]

External links

HGNC (Hugo)ERVE-1   14602
Entrez_Gene (NCBI)ERVE-1    endogenous retrovirus group E member 1
GeneCards (Weizmann)ERVE-1
Ensembl hg19 (Hinxton) [Gene_View]
Ensembl hg38 (Hinxton) [Gene_View]   [Sequence]  - [Contig_View]  ERVE-1 [Vega]
TCGA cBioPortalERVE-1
AceView (NCBI)ERVE-1
Genatlas (Paris)ERVE-1
SOURCE (Princeton)ERVE-1
Genetics Home Reference (NIH)ERVE-1
Genomic and cartography
GoldenPath hg38 (UCSC)ERVE-1  -  
GoldenPath hg19 (UCSC)ERVE-1  -  
GoldenPathERVE-1 - [CytoView hg19]  ERVE-1 - [CytoView hg38]
Genome Data Viewer NCBIERVE-1 [Mapview hg19]  
Gene and transcription
Genbank (Entrez)BC037342
RefSeq transcript (Entrez)
Consensus coding sequences : CCDS (NCBI)ERVE-1
Gene ExpressionERVE-1 [ NCBI-GEO ]   ERVE-1 [ EBI - ARRAY_EXPRESS ]   ERVE-1 [ SEEK ]   ERVE-1 [ MEM ]
Gene Expression Viewer (FireBrowse)ERVE-1 [ Firebrowse - Broad ]
GenevisibleExpression of ERVE-1 in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)85314
GTEX Portal (Tissue expression)ERVE-1
Protein : pattern, domain, 3D structure
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Conserved Domain (NCBI)ERVE-1
Protein Interaction databases
Ontologies - Pathways
PubMed6 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Oct 8 21:17:22 CEST 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us